Abstract 5007
Background
The majority of advanced non-small cell lung cancer (NSCLC) patients who receive PD-L1/PD-1 blockade immunotherapy as a second-line treatment do not respond. These treatments might not only affect the tumor microenvironment, but also alters the systemic dynamics of immune cell populations. Thus, the role of CD4 immunity in patients undergoing PD-L1/PD-1 blockade therapy remains unclear.
Methods
Peripheral blood samples from 51 NSCLC patients were obtained previous to the initiation of the PD-L1/PD-1 blockade therapy. Baseline T cell differentiation subsets based on CD27/CD28 expression were quantified by flow cytometry and correlated with responses. Baseline CD4 and CD8 T cells from NSCLC patients were co-cultured with T cell-stimulator cell line by expressing a membrane-bound anti-CD3 single-chain antibody in A549 human lung adenocarcinoma cells line (A549-SC3 cells) and PD-1, LAG-3 and Ki67 markers were assessed by flow cytometry.
Results
In our cohort study NSCLC patients were separated in two groups by a cut-off value of 40% CD4 THD (CD27-CD28low/-) cells: “G1 cohort” patients with more than 40% THD cells, and “G2 cohort” patients with less than 40%. Objective responders were found only within the G1 cohort (P = 0.0001). Interestingly, CD4 T cells from G2 patients were remarkably impaired in proliferation after ex vivo activation with A549-SC3 cells compared to CD4 T cells from G1 patients. CD8 T cells from both G1 and G2 patients were equally impaired in proliferation. CD4 T cells from G2 donors presented a significantly higher co-expression of PD-1 and LAG-3 compared with CD4 T cell from G1 donors after stimulation. CD4 T cells from both G1 and G2 patient cohorts were proficient in cytokine expression. Moreover, the proliferative capacities of CD8 T cells were recovered during after immunotherapy but only in patients with functional proliferative CD4 immunity.
Conclusions
This study uncovers that proliferative functionality of systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy. Moreover, CD4 T cells from G2 patients were not exhausted, indeed they responded to stimulation by producing cytokines although with strong co-upregulation of PD-1/LAG-3 associated with diminished proliferative capacities.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Immunomodulation group-Navarrabiomed Research Center.
Funding
Asociación Española Contra el Cáncer (AECC).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4868 - Evaluation of markers associated with efficacy of abiraterone acetate plus prednisone (AAP) in patients (pts) with castration-sensitive prostate cancer (mCSPC) from the LATITUDE study
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
4837 - LRP2, a potential new biomarker for Chinese younger aged intrahepatic cholangiocarcinoma patients
Presenter: Xiaoliang Shi
Session: Poster Display session 3
Resources:
Abstract
1286 - Reanalysis of the efficacy of molecular targeted agents (MTAs) given in the randomized trial SHIVA01 according to the ESMO ESCAT scale of actionability
Presenter: Aurelie Moreira
Session: Poster Display session 3
Resources:
Abstract
2736 - Comparison of Platforms for Determining Tumor Mutational Burden (TMB) From Blood Samples in Patients With Non-Small Cell Lung Cancer (NSCLC)
Presenter: Jonathan Baden
Session: Poster Display session 3
Resources:
Abstract
5045 - Comprehensive Pan-Cancer analysis of somatic mutations in drug transporters to reveal acquired and intrinsic drug resistance in 3149 metastatic cancer patients
Presenter: Sander Bins
Session: Poster Display session 3
Resources:
Abstract
4577 - Pan-Cancer Genomic Landscape of the Cyclin D1/FGF3,4,19 (11q13) Amplicon Including Associations with HPV Status, and ESR1 and AR Alterations
Presenter: Jennifer Johnson
Session: Poster Display session 3
Resources:
Abstract
5366 - Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients
Presenter: Xiaolong Jiao
Session: Poster Display session 3
Resources:
Abstract
4084 - Prospective comparative study of next-generation sequencing on fine needle aspirations versus core needle biopsies in cancer patients included in SHIVA02 trial
Presenter: Julien Masliah-Planchon
Session: Poster Display session 3
Resources:
Abstract
6017 - First national External Quality Assessement for the interpretation of somatic variants: assessment of 25 variants in colorectal, lung, ovarian cancers and melanoma in France
Presenter: Etienne Rouleau
Session: Poster Display session 3
Resources:
Abstract
2283 - Prospective testing of circulating tumor DNA in metastatic breast cancer facilitates clinical trial enrollment and precision oncology
Presenter: Andjelija Bujak
Session: Poster Display session 3
Resources:
Abstract